Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
Waxman
J
J
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London.
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003534:Cyproterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D003692:Delayed-Action Preparations; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011897:Random Allocation
D000726:Androgen Antagonists; D003692:Delayed-Action Preparations; D017373:Cyproterone Acetate; D005485:Flutamide; D003534:Cyproterone; D002064:Buserelin